Jin Takasaki
Overview
Explore the profile of Jin Takasaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
709
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duration of infectious virus shedding of SARS-CoV-2 Omicron variant among immunocompromised patients
Kamegai K, Itoh N, Ishikane M, Iwamoto N, Asai Y, Akazawa-Kai N, et al.
J Infect Chemother
. 2025 Jan;
31(4):102631.
PMID: 39848541
Objective: The duration of viral shedding and criteria for de-isolation in the hospital among immunocompromised patients with coronavirus disease 2019 (COVID-19) remain unclear. This study aimed to evaluate viral shedding...
2.
Hatano H, Suzuki M, Sugino M, Nakamura M, Kusaba Y, Tsujimoto Y, et al.
Respir Investig
. 2024 Nov;
62(6):1227-1232.
PMID: 39522366
Background: Nontuberculous mycobacterial pulmonary disease (NTM-PD) varies widely in clinical presentation, and some patients experience hemoptysis. Bronchial artery embolization (BAE) is a treatment option for hemoptysis caused by NTM-PD. However,...
3.
Katsuno T, Sugiura Y, Morishita M, Osaki S, Suzuki M, Takasaki J, et al.
Intern Med
. 2024 Aug;
PMID: 39135255
Echinococcosis, caused by Echinococcus spp., often affects the lungs and liver, and spinal involvement is rare. Echinococcus multilocularis is prevalent in Japan, particularly in Hokkaido. We herein report a rare...
4.
Tsukada A, Morita C, Shimizu Y, Uemura Y, Naka G, Takasaki J, et al.
Thorac Cancer
. 2024 Aug;
15(25):1854-1862.
PMID: 39086088
Background: Recent advancements in advanced non-small-cell lung cancer (NSCLC) treatment have significantly improved primary therapy outcomes owing to the emergence of various molecular targeted therapies and immune checkpoint inhibitors (ICIs)....
5.
Katagiri D, Tsukada A, Izumi S, Shimizu Y, Terada-Hirashima J, Uemura Y, et al.
Sci Rep
. 2024 May;
14(1):12550.
PMID: 38822071
Extracorporeal blood purification with polymyxin B immobilized fiber column direct hemoperfusion (PMX-DHP), is reported to be effective in treating COVID-19 pneumonitis with oxygen demand. This multicenter prospective study evaluated the...
6.
Katsuno T, Kimura M, Terada-Hirashima J, Kazuyama Y, Ikeda M, Moriya A, et al.
J Virol Methods
. 2024 Mar;
326:114909.
PMID: 38452822
This study aimed to evaluate diagnostic accuracy of SARS-CoV-2 RNA detection in saliva samples treated with a guanidine-based or guanidine-free inactivator, using nasopharyngeal swab samples (NPS) as referents. Based on...
7.
Tsukada A, Terada-Hirashima J, Takasaki J, Nokihara H, Izumi S, Hojo M, et al.
BMC Pulm Med
. 2024 Mar;
24(1):105.
PMID: 38431557
Background: While the prevalence of severe cases and mortality rate of coronavirus disease 2019 (COVID-19) appear to be reducing, the clinical characteristics and severity of hospitalized patients with asthma and...
8.
Sato L, Iwamoto N, Kakumoto Y, Tsuzuki S, Togano T, Ishikane M, et al.
J Atheroscler Thromb
. 2024 Feb;
31(8):1179-1193.
PMID: 38355124
Aim: Several studies have shown the efficacy and safety of low-molecular-weight heparin use in coronavirus disease 2019 (COVID-19), but that of unfractionated heparin (UFH) has not been investigated. We investigated...
9.
Morimoto K, Nonaka M, Yamazaki Y, Nakagawa T, Takasaki J, Tsuyuguchi K, et al.
Respir Investig
. 2024 Jan;
62(2):284-290.
PMID: 38277865
Background: CONVERT, a randomized, active-controlled, global, Phase 3 trial demonstrated that patients with treatment-refractory Mycobacterium avium complex (MAC) pulmonary disease were more likely to achieve culture conversion with amikacin liposome...
10.
Suzuki M, Matsunaga A, Miyoshi-Akiyama T, Terada-Hirashima J, Sadamasu K, Nagashima M, et al.
Drug Discov Ther
. 2023 Oct;
17(5):304-311.
PMID: 37899206
During an earlier multicenter, open-label, randomized controlled trial designed to evaluate the effectiveness of high-dose inhaled ciclesonide in patients with asymptomatic or mild coronavirus disease 2019 (COVID-19), we observed that...